Rompza and Isaac Sosa and junior Taylor Young

Distribution of medical literature suggesting a drug mayhave merit for an unapproved use is a marketing area that hasbeen in dispute for years. The FDA said "public health can be served when health-careprofessionals receive truthful and non-misleading scientificand medical information on unapproved uses." Industry critics say allowing companies to distribute theinformation promotes untested uses of drugs and may bedangerous. Consumer advocate Sidney Wolfe said the guidelines wereonly recommendations to companies, rather than a formalregulation, and should be reversed quickly after DemocratBarack Obama becomes president next week. A doctormay prescribe an antidepressant, for example, to treatinsomnia, or a cancer drug for a type of cancer beyond what isapproved. About one of five prescriptions in the United States waswritten to treat a condition for which the drug was notapproved, according to a 2006 study published in the Archivesof Internal Medicine. The researchers said most off-label useoccurs without scientific support Drugmakers welcomed the new FDA guidelines. Providing thestudies to doctors will help "assure that medical professionalsreceive timely and accurate medical information prior to thelengthy process" of securing FDA approval for wider use, saidKen Johnson, a spokesman for the Pharmaceutical Research andManufacturers of America.

Off-label use "can save lives, especially in practice areaswhere there are few effective treatments," he added. The FDA said articles circulated by companies should comefrom peer-reviewed journals that require disclosure ofconflicts of interest for researchers. It also encouragedcompanies to seek FDA approval for unapproved uses The guidelines also apply to medical device makers. The FDA proposed the guidelines in February 2008 and tookpublic comments before finalizing them.

(Reporting by Lisa Richwine; editing by Derek Caney, BrianMoss, Leslie Gevirtz) Stocks Regulatory News. With the loss of Jermaine Taylor, who last year scored 26.2 points per game and led the UCF mens basketball team in scoring in 29 of 31 games, the Knights are looking to a group of newcomers and returning starters to carry the scoring load. UCF is coming off a 17-14 season, in which they went 7-9 in conference USA and 13-3 at home. Here is a look at the 2009-2010 version of the Knights: GuardsDespite the loss of Taylor, the Knights welcome back three important players from the 2008 team in sophomores A.J. Rompza and Isaac Sosa, and junior Taylor Young.Rompza is coming off a freshman season in which he scored just 4.3 points per game, but led the team in assists per game (5.2), steals (46), and was second on the team in minutes, playing just more than 26 per game. This season, he will be called upon to look for his shot as well as create opportunities for his teammates.Sosa returns to the team after shooting a team-best 45 percent from three-point range last season. After playing for Puerto Rico in the offseason, Sosa will come into 2009 with more experience, and will be relied on for his sharp shooting around the perimeter.Young, one of two juniors on the 2009-2010 team, was second on the team in assists last year with 3.4 per game, but will also be counted on to improve on his scoring average (just 3.3 points) of a year ago.A trio of newcomers will be counted on to contribute as well for the Knights R.J.

Scott, Nik Garcia, and Marcus Jordan should all see significant playing time this season to help make up for the scoring loss of Taylor.Scott has a nice jump shot and can cause teams fits with his athleticism around the rim. Garcia is a lights-out shooter, and will be relied on to knock down shots from behind the three-point line. Forwards The strength of this team rests with the forwards, which include a wide array of talent in Dave Diakite, P.J Gaynor, A.J. Tyler, and Keith Clanton.Diakite sat out all last season with an injury and finally got the chance to show off his skills in the preseason.